A new blended genome genetic test being studied in a major clinical trial may help identify men at highest risk of aggressive prostate cancer and personalise screening strategies.

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, researchers are using the same tactics to advance prostate cancer treatment. A recent ...

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help ...